
    
      After being informed about the study and potential risk, all patients giving written informed
      consent will undergo a brief screening period to determine eligibility for the study. Once
      eligibility is confirmed, patients who meet the eligibility requirements will be randomized
      placebo control manner. Patient will be assigned to Xlear (2 puffs per nosetrils, every 3-4
      hours a day) or placebo. Patient will be followed for 1 week. Inflammatory markers will be
      obtained on Day 4 and repeat COVID-19 RT PCR on Day 7. Follow up will be done on Day 14 for
      all patients.
    
  